Clinical Trial Update: A Multicentre Study to Evaluate the Safety and Efficacy of AD 923 in Comparison to MSIR for the Treatment of CBP in Subjects [Phase 3]

View source ↗

Summary

A Phase 3 multicentre study evaluating AD 923 versus MSIR for the treatment of cancer-related pain and chronic back pain has been terminated; no efficacy or saf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Back Pain
• Cancer

Drugs mentioned

• AD 923
• MSIR (morphine sulfate)

Snippet

Sponsor: Sosei | Conditions: Cancer, Pain | Phase 3 | Status: TERMINATED